Regeneration Technologies , Inc.

Industry:

Medical Devices & Equipment

Description

RTI also holds the patents on BioCleanse, a proven tissue sterilization process validated to eliminate viruses, bacteria, fungi and spores from tissue without impacting the structural or biomechanical integrity of the tissue. The company has distributed more than half a million allograft implants sterilized with the BioCleanse process with zero incidence of infection. RTI is accredited by the American Association of Tissue Banks.

News Archive

ProChon Biotech Receives Genzyme Award for Excellence in Cartilage Research at ICRS World Congress. Blood Weekly; 9/17/2009 ...development of next-generation articular cartilage regeneration technologies. The research that has been recognized by...regeneration. ProChon's products combine cell regeneration technologies with proprietary growth factors and biocompatible... ...more

CoaLogix Announces Another Multi-Year Contract for SCR Management. PR Newswire; 8/4/2009 ...provider of SCR management services and catalyst regeneration technologies used by coal-fired power plants to reduce...reduction (SCR) management services and catalyst regeneration technologies used by coal-fired power plants to reduce... ...more

PRT Announces Nursery Closure and Site Consolidation. Marketwire Canada; 11/25/2009 ...2009 (Marketwire via COMTEX) -- Pacific Regeneration Technologies Inc. ("PRT") (TSX:PRT.UN) announced...be recorded in the fourth quarter. Pacific Regeneration Technologies Inc., is wholly owned by the PRT Forest Regeneration... ...more